Generic placeholder image

Recent Patents on Biotechnology

Editor-in-Chief

ISSN (Print): 1872-2083
ISSN (Online): 2212-4012

Monoclonal Antibodies as Cancer Therapeutics

Author(s): Jihene Elloumi, Karim Jellali, Ikram Jemel and Sami Aifa

Volume 6, Issue 1, 2012

Page: [45 - 56] Pages: 12

DOI: 10.2174/187220812799789190

Price: $65

Abstract

Three main targets were subjected for the most approved monoclonal antibodies (mAbs) in cancer therapy: EGFR in solid cancer, the clusters of differentiation in blood cancer and VEGF in angiogenesis. Meanwhile side effects, the elevated costs and resistance problems are limiting the efficiency of mAbs as targeted therapy. The combinatory therapy with chemo or radiotherapy has improved the efficiency of mAbs. The present review aims to shed more light on the immunotherapy and the related patents that were developed for cancer treatment.

Keywords: Cetuximab, Panitumumab, Nimutuzumab, trastuzumab, retuximab, ibritumumab, tozutumumab, ofamumumab, alemtuzumab, gemtuzumumab, Brentuximab, bevacizumab, ipilimumab, Neoplasms, immunotherapy, combinatory, United States Food and Drug Administration, patents.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy